The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer
Open accessAbstract
BACKGROUND: Discovery of cancer drivers is a major goal of cancer research. Driver genes and pathways are often predicted using mutation frequency, assuming that statistically significant recurrence of specific somatic mutations across independent samples indicates their importance in cancer. However, many mutations, including known cancer drivers, are not observed at high frequency. Fortunately, abundant information is available about functional "active sites" in proteins that can be integrated with mutations to predict cancer driver genes, even based on low frequency mutations. Further, considering active site information predicts detailed biochemical mechanisms impacted by the mutations. Post-translational modifications (PTMs) are active sites that are regulatory switches in proteins and pathways. We analyzed acetylation and ubiquitination, two important PTM types often involved in chromatin organization and protein degradation, to find proteins that are significantly affected by tumor somatic mutations. METHODS: We performed computational analyses of acetylation and ubiquitination sites in a pan-cancer dataset of 3200 tumor samples from The Cancer Genome Atlas (TCGA). These analyses were targeted at different levels of biological organization including individual genes, pathway annotated gene sets, and protein-protein interaction networks. RESULTS: Acetylation and ubiquitination site mutations are enriched in cancer with significantly stronger evolutionary conservation and accumulation in protein domains. Gene-focused analysis with the ActiveDriver method reveals significant co-occurrences of acetylation and ubiquitination PTMs and mutation hotspots in known oncoproteins (TP53, AKT1, IDH1) and highlights candidate cancer driver genes with PTM-related mechanisms (e.g. several histone proteins and the splicing factor SF3B1). Pathway analysis shows that PTM mutations in acetylation and ubiquitination sites accumulate in cancer-related processes such as cell cycle, apoptosis, chromatin regulation, and metabolism. Integrated mutation analysis of clinical information and protein interaction networks suggests that many PTM-specific mutations associate with decreased patient survival. CONCLUSIONS: Mutation analysis of acetylation and ubiquitination PTM sites reveals their importance in cancer. As PTM networks are increasingly mapped and related enzymes are often druggable, deeper investigation of specific associated mutations may lead to the discovery of treatment-relevant cellular mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mutations at acetylation sites are commonly found in tumor tissues within key cellular pathways, such as the cell cycle, metabolism, and apoptosis [14].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 2×
“These cancer driver events modify cellular pathways and provide cells with selective advantages such as uncontrolled growth, suppressed apoptosis, replicative immortality, and mobility [1].”
BackgroundCytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206 · cited 6×
“We studied biological processes from Gene Ontology [43], pathways from Reactome [44], and protein complexes from CORUM [45].”
MethodInfluentialANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 2×
“Chromosomal coordinates of mutations were converted to protein-level substitutions using the Annovar software [36] and filtered for the longest isoforms defined above.”
MethodThe Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194 · cited 1×
“We also scored PTM-related mutations by integrating results from five predictors of variant function (SIFT [56], PolyPhen2 [57], LRT [58], PhyloP [59], MutationTaster [60]), as collected by the Annovar software [36].”
MethodJenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Such approaches are complicated by mutational heterogeneity, as mutation rates vary across genes, and nucleotide signatures [8, 10, 11], and are influenced by factors such as gene expression intensity [12], DNA replication timing [13], and chromatin organization [14].”
BackgroundThe cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092 · cited 5×
“We retrieved the pre-processed pan-cancer dataset of somatic mutations in 3185 tumor samples curated by the TCGA for 12 different cancer types [5, 35] from the Synapse repository (ID syn1729383).”
BackgroundMethodInfluentialVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Cited by
Mutations in Disordered Regions Can Cause Disease by Creating Dileucine Motifs
Meyer, K., Kirchner, M., Uyar, B., Cheng, J.-Y., Russo, G., Hernandez-Miranda, L. R., Szymborska, A., Zauber, H., Rudolph, I.-M., Willnow, T. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.019 · Cited by 132
“For each of these classes, the number of disease-causing variants and the number of polymorphisms that lead to a gain of SLiMs was counted and a two-sided Fisher’s Exact Test was applied to see if there is a statistically significant difference for the likelihood of a given class of SLiMs to be gained via disease-caus…”
InfluentialBioinformatics in translational drug discovery
Wooller, S. K., Benstead-Hume, G., Chen, X., Ali, Y., & Pearl, F. M. G. (2017) · Bioscience Reports · doi:10.1042/bsr20160180 · Cited by 145
Krassowski, M., Paczkowska, M., Cullion, K., Huang, T., Dzneladze, I., Ouellette, B. F. F., Yamada, J. T., Fradet‐Turcotte, A., & Reimand, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx973 · Cited by 101
“To address this limitation, we developed the ActiveDriverDB database, a proteo-genomics resource for interpreting human genome variation using information on post-translational modification sites in proteins (24-27).”
BackgroundMethodSelf-citationModeling the process of human tumorigenesis
Balani, S., Nguyen, L. V., & Eaves, C. J. (2017) · Nature Communications · doi:10.1038/ncomms15422 · Cited by 86
Novel Serine 176 Phosphorylation of YBX1 Activates NF-κB in Colon Cancer
Martin, M., Hua, L., Wang, B., Han, W., Prabhu, L., Hartley, A.-V., Jiang, G., Liu, Y., & Lu, T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.740258 · Cited by 64
“PTM is one of the key approaches that mammalian cells use to control gene expression and cellular functions in a sophisticated manner (21, 22).”
Background
Metadata
- Authors
- Narayan, S., Bader, G. D., & Reimand, J.
- Affiliations
- University of Toronto (CA)
- Ontario Institute for Cancer Research (CA)
- Corresponding author
- Bader, Gary D.
- Reimand, Jüri
- Venue
- Genome Medicine
- Published
- 2016-05-12
- Volume
- 8
- Issue
- 1
- Pages
- 55-55
- ISSN
- 1756-994X (ISSN-L)
- PMC
- PMC4864925
- OpenAlex
- W2352710988
- Cited by
- 54
- References
- 80
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 3 · 2019: 5 · 2018: 6 · 2017: 10 · 2016: 1
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Genome Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP-84324)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- cancer driver genes, somatic mutations, acetylation sites, ubiquitination sites, post-translational modification, mutational hotspots, histone acetylation, SF3B1, TP53, AKT1, IDH1, chromatin regulation, protein-protein interaction network, patient survival, pan-cancer analysis
- MeSH terms
- Acetylation, Humans, Mutation, Neoplasm Proteins, Neoplasms, Protein Processing, Post-Translational, Survival Analysis, Computational Biology, Genetic Predisposition to Disease, Databases, Genetic, Gene Regulatory Networks, Ubiquitination, Mutation Rate, Protein Interaction Maps
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer. https://app.cochat.ai/papers/10.1186/s13073-016-0311-2
- The paper
- Narayan, S., Bader, G. D., & Reimand, J. (2016). Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer. Genome Medicine. https://doi.org/10.1186/s13073-016-0311-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.